Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Liver

Liver

36

Pipeline Programs↗

59

Active Trials↗

39

Companies Involved↗

Liver is a moderately active landscape with 36 programs across 39 companies. The most active players are Gilead, GSK, Eli Lilly. 12 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

53/100

Mech. Concentration

22/100

Completion Rate

86/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Gilead

1 program

GSK

1 program

Eli Lilly

1 program

Ganzhou Hemay Pharmaceutical Co., Ltd

1 program

Hudson Biotech

1 program

Resolution Therapeutics Limited

1 program

Pipeline

Programs by Phase

Preclinical13

RTX001

Resolution Therapeutics Limited

Efavirenz

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Nicotine Free Cigarettes

Pfizer

Nicotine Lozenge

Fertin Pharma A/S

Tesamorelin

Theratechnologies

Phase 17

Yttrium-90

University Health Network, Toronto

CNS10-NPC-GDNF

Cedars-Sinai Medical Center

Hemay005

Ganzhou Hemay Pharmaceutical Co., Ltd

Control Session

Caroline Samer

Inhibition Session

Caroline Samer

Phase 24

Immunosuppression Reduction

Massachusetts General Hospital

GSK4532990

GSK

Semaglutide

Novo Nordisk

Erlotinib Hydrochloride

University of Texas Southwestern Medical Center

Phase 312

Everolimus

Novartis

CAZ-AVI

Pfizer

Meropenem-Vaborbactam

Melinta Therapeutics, Inc.

Imipenem+relebactam

Wake Forest University Health Sciences

Cefiderocol

Shionogi

Approved

No programs

Analysis

Modality Breakdown

94%

Small molecule

32 of 34 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 97% of 36 pipeline programs.

Analysis

Trial Status

197

clinical trials

Completed106 · 54%

Recruiting29 · 15%

Active, not recruiting14 · 7%

Unknown status13 · 7%

Not yet recruiting12 · 6%

Terminated10 · 5%

Other13 · 7%

Clinical Trials

Trial Activity

197 trials

A Dose-finding, Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of Treatment With Efimosfermin Alfa in Adult Participants With Alcohol-related Liver Disease (ALD)

Recruiting· GSK logo

GSK·Phase 2·NCT07791043·274 enrolled

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (CTOT-43)

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06280950·340 enrolled

Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation (RTB-018)

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07549503·100 enrolled

Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates (CTOT-44)

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06075745·416 enrolled

Interdisciplinary Project on Liver Health With a Focus on Steatotic Changes - Pilot Project of the Radiologic Technology, Dietetics, and Biomedical Analysis Programs

Recruiting·Hochschule Campus Wien (University of Applied Sciences Campus Vienna)·Preclinical·NCT07786831·100 enrolled

Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe (REFRAME-MP)

Recruiting·UUniversity Medical Center Groningen·N/A·NCT07585890·10,000 enrolled

Role of Allopurinol in Prevention of Complications Related to Decompensated Cirrhosis of Liver'

Recruiting·BBangladesh Medical University·Approved·NCT07800598·54 enrolled

PREDICTT Clinical Trial: Prospective Evaluation Of Pressure-Enabled Delivery And Alterations In CT-Based Tumor-To-Normal Liver Ratio And Tumor Dose Using The Trinav Infusion System

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT07444645·20 enrolled

Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Patients Undergoing Open Liver Resection Surgery

Recruiting·CCairo University·Preclinical·NCT06621472·90 enrolled

Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Recruiting·TThe Cleveland Clinic·Preclinical·NCT03208868·32 enrolled

Safety and Feasibility of Second-Generation Laryngeal Mask Airway Versus Endotracheal Intubation for Anesthesia in Adult Liver Transplantation: A Multicenter, Prospective, Randomized Controlled Clinical Trial

Recruiting·GGuangzhou Medical University·Preclinical·NCT07775521·100 enrolled

Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Volunteers on Clinical Trials Utilising Machine-learning and Bioimpedance Vector Analysis

Recruiting·Richmond Research Institute·N/A·NCT04873258·2,000 enrolled

Cross-sectional Study for Assessment of MRI Based Biomarkers of Bile Duct Injury and Hepatic Fibrosis in Pediatric Onset Autoimmune Liver Disease

Recruiting·CChildren's Hospital Medical Center, Cincinnati·N/A·NCT03175471·115 enrolled

Longitudinal Study for the Assessment of MRI Based Biomarkers as a Predictors of Clinical Endpoints in Pediatric Onset Autoimmune Liver Disease

Recruiting·CChildren's Hospital Medical Center, Cincinnati·N/A·NCT03178630·150 enrolled

Multicenter Clinical Study on Noninvasive Assessment of Hepatic Steatosis and Fibrosis Using Visual Transient Elastography

Recruiting·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT07128108·225 enrolled

Page 1 of 14

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)